Abstract
Curcumin, a natural bioactive polyphenol, has been widely investigated as a conventional medicine for centuries. Over the past two decades, major pre-clinical and clinical trials have demonstrated its safe therapeutic profile but clinical translation has been hampered due to rapid degradation, poor water solubility, bioavailability and pharmaco-kinetics. To overcome such translational issues, many laboratories have focused on developing curcumin nanoformulations for cancer therapeutics. In this review, we discuss the evolution of curcumin nanomedicine in cancer therapeutics, the possible interactions between the surface of curcumin nanoparticles and plasma proteins, the role of nanoparticle-protein complex architecture parameters, and the rational design of clinically useful curcumin nanoformulations. Considering all the biologically relevant phenomena, curcumin nanoformulations can be developed as a new neutraceutical or pharmaceutical agent.
Keywords: Polyphenol, drug delivery, nanomedicine, cancer therapeutics, bioavailability, protein corona.
Current Drug Metabolism
Title:Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics
Volume: 14 Issue: 4
Author(s): Murali M. Yallapu, Mara C. Ebeling, Meena Jaggi and Subhash C. Chauhan
Affiliation:
Keywords: Polyphenol, drug delivery, nanomedicine, cancer therapeutics, bioavailability, protein corona.
Abstract: Curcumin, a natural bioactive polyphenol, has been widely investigated as a conventional medicine for centuries. Over the past two decades, major pre-clinical and clinical trials have demonstrated its safe therapeutic profile but clinical translation has been hampered due to rapid degradation, poor water solubility, bioavailability and pharmaco-kinetics. To overcome such translational issues, many laboratories have focused on developing curcumin nanoformulations for cancer therapeutics. In this review, we discuss the evolution of curcumin nanomedicine in cancer therapeutics, the possible interactions between the surface of curcumin nanoparticles and plasma proteins, the role of nanoparticle-protein complex architecture parameters, and the rational design of clinically useful curcumin nanoformulations. Considering all the biologically relevant phenomena, curcumin nanoformulations can be developed as a new neutraceutical or pharmaceutical agent.
Export Options
About this article
Cite this article as:
Yallapu Murali M., Ebeling Mara C., Jaggi Meena and Chauhan Subhash C., Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics, Current Drug Metabolism 2013; 14 (4) . https://dx.doi.org/10.2174/1389200211314040012
DOI https://dx.doi.org/10.2174/1389200211314040012 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ubiquitylation and Cancer Development
Current Cancer Drug Targets Cholesterol-Rich Nanoemulsions (LDE) for Drug Targeting of Cholesteryl-Succinyl- 5-Fluorouracil Conjugate
Current Nanoscience Robotic Assisted Surgery in Gynecology: Current Insights and Future Perspectives
Recent Patents on Biotechnology Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Diagnosis and Prognostic Evaluation for Xerostomia Using Dynamic MR Sialography
Current Medical Imaging Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Peptides in Oral Diseases
Current Pharmaceutical Design Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
Current Drug Targets